Product Code: BT 4224
The single-cell analysis market is projected to reach USD 6.9 billion by 2029 from an estimated USD 3.7 billion in 2024, at a CAGR of 13.6% during the forecast period from 2024 to 2029. The growth of this market can be attributed to the increasing focus on personalized medicine. The rising R&D investments pharmaceutical & biotechnology industries is propelling the growth of single-cell analysis. Additionally, factors such as growth in stem cell research and technological advancements in single-cell analysis products are expected to contribute to the growth of single-cell analysis market. Also, growing incidences of cancer is promoting the need of advanced therapies resulting to boost the growth of single-cell analysis market. Moreover, rising adoption of advanced single-cell sequencing technique is expected to propel the market growth in coming years.
Scope of the Report |
Years Considered for the Study | 2022-2029 |
Base Year | 2023 |
Forecast Period | 2024-2029 |
Units Considered | Value (USD Billion) |
Segments | Product, Cell Type, Technique, Application, and End User |
Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
"The research application segment accounted for the largest share of by application segment in 2023."
Based on application, single-cell analysis market is segmented into research application and medical application. Research application further categories into cancer research, immunology research, neurology research, stem cell research, and other research applications. Similarly, medical research is divided into non invasive prenatal diagnosis, in vitro fertilization, and circulating tumour cell detection. In 2023, the research application segment accounted for the largest share of the global single-cell analysis market by application. Increasing prevalence of cancer is driving the need of advanced thearpies resulting to promote segment's growth in the single-cell analysis market. Additionally, growth in stem cell research is anticipated to promote the segment's growth in single-cell analysis market.
"The flow cytometry segment accounted for the major share of by technology segment in 2023."
Based on technology, single-cell analysis market is segmented into flow cytometry, next-generation sequencing, polymerase chain reaction, microscopy, mass spectrometry, and other techniques. In 2023, the flow cytometry segment accounted for the major share of the global single-cell analysis market by technology. The growth of the flow cytometry segment is primarily attributed to the wide usage of flow cytometry in single-cell analysis application due to its ability to perform multiple measurements within heterogeneous mixture. Additionally, growing adoption of advanced technologies for cell identification and cell characterization is anticipated to boost the segment growth in single-cell analysis market.
"The US has continued to dominate the single-cell analysis market in 2023."
Based on the region, the single-cell analysis market is segmented into six major regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, US dominated the single-cell analysis market in North America. The US is the world's largest biopharmaceutical market and a leader in biopharmaceutical research/investments. The US also has a strong healthcare infrastructure, which drives research and development in the life sciences sector. Additionally, the significant presence of many biopharmaceutical companies and growing research activities in the biotechnology industry are propelling market growth in the US. Moreover, growing focus on development of personalized medicine due to growing incidences of cancer is also driving the growth of the single-cell analysis market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America - 40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
List of Companies Profiled in the Report:
- Thermo Fisher Scientific Inc. (US)
- Danaher Corporation (US)
- Merck KGaA (Germany)
- BD (US)
- Agilent Technologies, Inc. (US)
- QIAGEN (Netherlands)
- 10x Genomics (US)
- Illumina, Inc. (US)
- Bio-Rad Laboratories, Inc. (US)
- DiaSorin S.p.A. (Italy)
- Standard BioTools (US)
- Tecan Trading AG (Switzerland)
- Sartorius AG (Germany)
- Corning Incorporated (US)
- Cytek Biosciences (US)
- Takara Bio Inc. (Japan)
- BIOMERIEUX (France)
- Revvity (US)
- Bio-Techne (US)
- PacBio (US)
- Bruker (US)
- Promega Corporation (US)
- Oxford Nanopore Technologies plc. (UK)
- The Menarini Group (Italy)
- Singleron Biotechnologies (Germany)
- BICO (Sweden)
- Fluent BioSciences (US)
- RareCyte, Inc. (US)
- Cell Microsystems (US)
- NanoCellect Biomedical (US)
- Sphere Fluidics (UK)
- On-chip Biotechnologies Co., Ltd. Corporation (Japan)
- Apogee Flow Systems Ltd. (UK)Merck KGaA (Germany)
Research Coverage:
This research report categorizes the single-cell analysis market by product (consumables (reagents, assay kits (immuno assays and cell based assays), beads, microplates, and other consumables) and instruments(PCR instruments, NGS systems, flow cytometers, spectrophotometers, cell counters, microscopes, HCS systems, microarrays, and other instruments)), cell type (human cells, animal cells, and microbial cells), technique (flow cytometry, next-generation sequencing, microscopy, polymerase chain reaction, mass spectrometry, and other techniques), application (research application (cancer research, immunology research, neurology research, stem cell research, other research applications) and medical application (non invasive prenatal diagnosis, in vitro fertilization, and circulating tumour cell detection), end user (academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centers), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the single-cell analysis market. A thorough analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. Also, it includes new product launches, collaborations and acquisitions, and recent developments associated with the single-cell analysis market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall single-cell analysis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (technological advancements in single-cell analysis products, surge in cases of cancer, and increasing R&D in pharmaceutical & biotechnology industries for complex diseases), restraints (high cost of single-cell analysis products), opportunities (integration of microfluidics in single-cell analysis), and Challenges (standardization of protocols and data integration & quality control for developing cell therapies) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the single-cell analysis market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the single-cell analysis market
- Competitive Assessment: . Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), BD (US), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), 10x Genomics (US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), DiaSorin S.p.A. (Italy), Standard BioTools (US), Tecan Trading AG (Switzerland), Sartorius AG (Germany), Corning Incorporated (US), Cytek Biosciences (US), Takara Bio Inc. (Japan), BIOMERIEUX (France), Revvity (US), Bio-Techne (US), PacBio (US), Bruker (US), Promega Corporation (US), Oxford Nanopore Technologies plc. (UK), The Menarini Group (Italy), Singleron Biotechnologies (Germany), BICO (Sweden), Fluent BioSciences (US), RareCyte, Inc. (US), Cell Microsystems (US), NanoCellect Biomedical (US), Sphere Fluidics (UK), On-chip Biotechnologies Co., Ltd. Corporation (Japan), and Apogee Flow Systems Ltd. (UK), among others in the market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
- 1.3.2 YEARS CONSIDERED
- 1.3.3 INCLUSIONS AND EXCLUSIONS
- 1.4 CURRENCY CONSIDERED
- 1.5 UNIT CONSIDERED
- 1.6 STAKEHOLDERS
- 1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.2 PRIMARY DATA
- 2.2 MARKET SIZE ESTIMATION METHODOLOGY
- 2.2.1 GLOBAL SINGLE-CELL ANALYSIS MARKET SIZE ESTIMATION, 2023
- 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
- 2.2.3 TOP-DOWN APPROACH
- 2.3 MARKET GROWTH RATE PROJECTIONS
- 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RISK ANALYSIS
- 2.7 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN SINGLE-CELL ANALYSIS MARKET
- 4.2 SINGLE-CELL ANALYSIS MARKET IN NORTH AMERICA, BY CELL TYPE AND COUNTRY
- 4.3 SINGLE-CELL ANALYSIS MARKET, BY PRODUCT
- 4.4 SINGLE-CELL ANALYSIS MARKET, BY END USER
- 4.5 SINGLE-CELL ANALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Technological advancements in single-cell analysis products
- 5.2.1.2 Rising prevalence of cancer
- 5.2.1.3 Increasing R&D in pharmaceutical and biotechnology industries
- 5.2.1.4 Growth in stem cell research
- 5.2.1.5 Growing focus on personalized medicine
- 5.2.2 RESTRAINTS
- 5.2.2.1 High cost of single-cell analysis products
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 High growth potential of single-cell sequencing
- 5.2.3.2 Integration of microfluidics in single-cell analysis
- 5.2.3.3 Rising potential in emerging Asian markets
- 5.2.4 CHALLENGES
- 5.2.4.1 Lack of standardization in protocols and quality control procedures
- 5.2.4.2 Technical limitations of single-cell analysis
- 5.2.4.3 Mounting ethical and privacy concerns
- 5.3 TECHNOLOGY ANALYSIS
- 5.3.1 KEY TECHNOLOGIES
- 5.3.1.1 Flow cytometry
- 5.3.1.2 Next-generation sequencing
- 5.3.1.3 Polymerase chain reaction
- 5.3.1.4 Microscopy
- 5.3.1.5 Mass spectrometry
- 5.3.2 COMPLEMENTARY TECHNOLOGIES
- 5.3.2.1 Bioinformatics tools and computational analysis
- 5.3.2.2 Multi-omics integration
- 5.3.3 ADJACENT TECHNOLOGIES
- 5.3.3.1 Nanotechnology
- 5.3.3.2 Artificial intelligence and machine learning
- 5.4 SUPPLY CHAIN ANALYSIS
- 5.5 VALUE CHAIN ANALYSIS
- 5.6 PRICING ANALYSIS
- 5.7 ECOSYSTEM ANALYSIS
- 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.9 PATENT ANALYSIS
- 5.9.1 METHODOLOGY
- 5.9.2 PATENTS APPLIED AND GRANTED, 2014-2024
- 5.10 KEY CONFERENCES AND EVENTS, 2024-2025
- 5.11 REGULATORY LANDSCAPE
- 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.11.2 REGULATIONS
- 5.12 PORTER'S FIVE FORCES ANALYSIS
- 5.12.1 THREAT OF NEW ENTRANTS
- 5.12.2 THREAT OF SUBSTITUTES
- 5.12.3 BARGAINING POWER OF SUPPLIERS
- 5.12.4 BARGAINING POWER OF BUYERS
- 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.13.2 ROLE OF STAKEHOLDERS IN BUYING PROCESS
- 5.13.3 BUYING CRITERIA
- 5.14 INVESTMENT AND FUNDING SCENARIO
- 5.15 TRADE ANALYSIS
- 5.15.1 IMPORT DATA (HS CODE 9027)
- 5.15.2 EXPORT DATA (HS CODE 9027)
- 5.16 IMPACT OF GENERATIVE AI ON SINGLE-CELL ANALYSIS MARKET
6 SINGLE-CELL ANALYSIS MARKET, BY PRODUCT
- 6.1 INTRODUCTION
- 6.2 CONSUMABLES
- 6.2.1 BEADS
- 6.2.1.1 Increasing use in research and genetic exploration to drive market
- 6.2.2 MICROPLATES
- 6.2.2.1 Rising frequency of product launches to boost market
- 6.2.3 REAGENTS
- 6.2.3.1 Advancements in single-cell genomics to increase demand
- 6.2.4 ASSAY KITS
- 6.2.4.1 Immunoassays
- 6.2.4.1.1 Growth in geriatric population to fuel demand
- 6.2.4.2 Cell-based assays
- 6.2.4.2.1 Increasing use in pharma and biopharma companies to drive market
- 6.2.5 OTHER CONSUMABLES
- 6.3 INSTRUMENTS
- 6.3.1 FLOW CYTOMETERS
- 6.3.1.1 Technological advancements to drive demand
- 6.3.2 NGS SYSTEMS
- 6.3.2.1 Increased affordability to support segment growth
- 6.3.3 PCR INSTRUMENTS
- 6.3.3.1 Rising use for DNA and mRNA amplification to boost market
- 6.3.4 SPECTROPHOTOMETERS
- 6.3.4.1 Technological advancements to boost market
- 6.3.5 CELL COUNTERS
- 6.3.5.1 Rising demand for automated cell counters to fuel market
- 6.3.6 MICROSCOPES
- 6.3.6.1 Increasing use in cell-based research to drive market
- 6.3.7 HCS SYSTEMS
- 6.3.7.1 Growing need for multi-parametric cell analysis to drive adoption
- 6.3.8 MICROARRAYS
- 6.3.8.1 Increasing development of targeted therapies to support market
- 6.3.9 OTHER INSTRUMENTS
7 SINGLE-CELL ANALYSIS MARKET, BY CELL TYPE
- 7.1 INTRODUCTION
- 7.2 HUMAN CELLS
- 7.2.1 GROWING FUNDING FOR CANCER RESEARCH TO BOOST DEMAND
- 7.3 ANIMAL CELLS
- 7.3.1 INCREASING ANIMAL CELL RESEARCH TO DRIVE MARKET
- 7.4 MICROBIAL CELLS
- 7.4.1 RISING GOVERNMENT SUPPORT TO COMBAT ANTIMICROBIAL RESISTANCE TO PROPEL MARKET
8 SINGLE-CELL ANALYSIS MARKET, BY TECHNIQUE
- 8.1 INTRODUCTION
- 8.2 FLOW CYTOMETRY
- 8.2.1 INCREASING USE TO IDENTIFY CANCEROUS CELLS TO DRIVE MARKET
- 8.3 NEXT-GENERATION SEQUENCING
- 8.3.1 WIDE ADOPTION IN DRUG DISCOVERY TO DRIVE MARKET
- 8.4 POLYMERASE CHAIN REACTION
- 8.4.1 INCREASING APPLICATIONS OF DIGITAL PCR TO SUPPORT MARKET
- 8.5 MICROSCOPY
- 8.5.1 FOCUS ON DEVELOPMENT OF ADVANCED IMAGING SYSTEMS TO PROPEL MARKET
- 8.6 MASS SPECTROMETRY
- 8.6.1 LAUNCH OF ADVANCED PRODUCTS TO DRIVE MARKET
- 8.7 OTHER TECHNIQUES
9 SINGLE-CELL ANALYSIS MARKET, BY APPLICATION
- 9.1 INTRODUCTION
- 9.2 RESEARCH APPLICATIONS
- 9.2.1 CANCER RESEARCH
- 9.2.1.1 Rising prevalence of cancer to drive market
- 9.2.2 IMMUNOLOGY RESEARCH
- 9.2.2.1 High incidence of immunological disorders to propel market
- 9.2.3 NEUROLOGY RESEARCH
- 9.2.3.1 Increasing incidence of neurological disorders to boost market
- 9.2.4 STEM CELL RESEARCH
- 9.2.4.1 Rising investments in stem cell research to drive market
- 9.2.5 OTHER RESEARCH APPLICATIONS
- 9.3 MEDICAL APPLICATIONS
- 9.3.1 NON-INVASIVE PRENATAL DIAGNOSIS
- 9.3.1.1 Increasing prevalence of genetic diseases to drive demand
- 9.3.2 IN VITRO FERTILIZATION
- 9.3.2.1 Growing demand for IVF procedures to support market
- 9.3.3 CIRCULATING TUMOR CELL DETECTION
- 9.3.3.1 Rising prevalence of cancer to contribute to segment growth
10 SINGLE-CELL ANALYSIS MARKET, BY END USER
- 10.1 INTRODUCTION
- 10.2 ACADEMIC & RESEARCH LABORATORIES
- 10.2.1 INCREASING FUNDING FOR LIFE SCIENCE RESEARCH TO DRIVE MARKET
- 10.3 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
- 10.3.1 GROWTH IN DRUG DISCOVERY AND R&D ACTIVITIES TO BOOST MARKET
- 10.4 HOSPITALS & DIAGNOSTIC LABORATORIES
- 10.4.1 HIGH PREVALENCE OF INFECTIOUS AND CHRONIC DISEASES TO DRIVE DEMAND
- 10.5 CELL BANKS & IVF CENTERS
- 10.5.1 RISING DEMAND FOR PERSONALIZED AND REGENERATIVE MEDICINE TO PROPEL MARKET
11 SINGLE-CELL ANALYSIS MARKET, BY REGION
- 11.1 INTRODUCTION
- 11.2 NORTH AMERICA
- 11.2.1 US
- 11.2.1.1 Increasing R&D investments and funding to drive market
- 11.2.2 CANADA
- 11.2.2.1 High prevalence of hemophilia to propel market
- 11.3 EUROPE
- 11.3.1 GERMANY
- 11.3.1.1 Growing awareness of advanced cell therapies to support market
- 11.3.2 UK
- 11.3.2.1 Growing adoption of single-cell analysis products to drive demand
- 11.3.3 FRANCE
- 11.3.3.1 Growing government funding for R&D to propel market
- 11.3.4 ITALY
- 11.3.4.1 Focus on cell biology research to drive market
- 11.3.5 SPAIN
- 11.3.5.1 Increasing number of biotechnology companies to drive demand
- 11.3.6 REST OF EUROPE
- 11.4 ASIA PACIFIC
- 11.4.1 CHINA
- 11.4.1.1 Increasing R&D expenditure to support market
- 11.4.2 JAPAN
- 11.4.2.1 Increasing geriatric population to fuel demand
- 11.4.3 INDIA
- 11.4.3.1 Growing focus on development of cell-based therapies to boost market
- 11.4.4 SOUTH KOREA
- 11.4.4.1 Increasing number of strategic alliances to boost market
- 11.4.5 AUSTRALIA
- 11.4.5.1 Rising number of life science companies to boost demand
- 11.4.6 REST OF ASIA PACIFIC
- 11.5 LATIN AMERICA
- 11.5.1 BRAZIL
- 11.5.1.1 Rising focus on biotechnology industry to bolster market
- 11.5.2 MEXICO
- 11.5.2.1 Government support for biopharmaceutical production to drive market
- 11.5.3 REST OF LATIN AMERICA
- 11.6 MIDDLE EAST
- 11.6.1 GCC
- 11.6.1.1 Focus on advancement of local biopharmaceutical industry to drive market
- 11.6.1.2 Saudi Arabia
- 11.6.1.2.1 Increasing healthcare expenditure to drive market
- 11.6.1.3 United Arab Emirates
- 11.6.1.3.1 Advancements in biopharmaceutical sector to drive demand
- 11.6.1.4 Rest of GCC
- 11.6.2 REST OF MIDDLE EAST
- 11.7 AFRICA
- 11.7.1 GROWING FUNDING FOR DEVELOPMENT AND PRODUCTION OF BIOPHARMACEUTICALS TO DRIVE MARKET
12 COMPETITIVE LANDSCAPE
- 12.1 OVERVIEW
- 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023
- 12.3 REVENUE ANALYSIS, 2021-2023
- 12.4 MARKET SHARE ANALYSIS, 2023
- 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 12.5.1 STARS
- 12.5.2 EMERGING LEADERS
- 12.5.3 PERVASIVE PLAYERS
- 12.5.4 PARTICIPANTS
- 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 12.5.5.1 Company footprint
- 12.5.5.2 Product footprint
- 12.5.5.3 Region footprint
- 12.5.5.4 Technique footprint
- 12.5.5.5 Application footprint
- 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 12.6.1 PROGRESSIVE COMPANIES
- 12.6.2 RESPONSIVE COMPANIES
- 12.6.3 DYNAMIC COMPANIES
- 12.6.4 STARTING BLOCKS
- 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 12.6.5.1 Detailed list of key startups/SMEs
- 12.6.5.2 Competitive benchmarking of key startups/SMEs
- 12.7 COMPANY VALUATION AND FINANCIAL METRICS
- 12.8 BRAND/PRODUCT COMPARISON
- 12.9 COMPETITIVE SCENARIO AND TRENDS
- 12.9.1 PRODUCT LAUNCHES & APPROVALS
- 12.9.2 DEALS
- 12.9.3 EXPANSIONS
13 COMPANY PROFILES
- 13.1 INTRODUCTION
- 13.2 KEY PLAYERS
- 13.2.1 BD
- 13.2.1.1 Business overview
- 13.2.1.2 Products offered
- 13.2.1.3 Recent developments
- 13.2.1.3.1 Product launches & approvals
- 13.2.1.3.2 Deals
- 13.2.1.4 MnM view
- 13.2.1.4.1 Key strengths
- 13.2.1.4.2 Strategic choices
- 13.2.1.4.3 Weaknesses and competitive threats
- 13.2.2 THERMO FISHER SCIENTIFIC INC.
- 13.2.2.1 Business overview
- 13.2.2.2 Products offered
- 13.2.2.3 Recent developments
- 13.2.2.3.1 Product launches & approvals
- 13.2.2.3.2 Deals
- 13.2.2.4 MnM view
- 13.2.2.4.1 Key strengths
- 13.2.2.4.2 Strategic choices
- 13.2.2.4.3 Weaknesses and competitive threats
- 13.2.3 DANAHER CORPORATION
- 13.2.3.1 Business overview
- 13.2.3.2 Products offered
- 13.2.3.3 Recent developments
- 13.2.3.4 MnM view
- 13.2.3.4.1 Key strengths
- 13.2.3.4.2 Strategic choices
- 13.2.3.4.3 Weaknesses and competitive threats
- 13.2.4 10X GENOMICS
- 13.2.4.1 Business overview
- 13.2.4.2 Products offered
- 13.2.4.3 Recent developments
- 13.2.4.3.1 Product launches & approvals
- 13.2.4.3.2 Deals
- 13.2.5 MERCK KGAA
- 13.2.5.1 Business overview
- 13.2.5.2 Products offered
- 13.2.5.3 Recent developments
- 13.2.6 AGILENT TECHNOLOGIES, INC.
- 13.2.6.1 Business overview
- 13.2.6.2 Products offered
- 13.2.6.3 Recent developments
- 13.2.6.3.1 Product launches & approvals
- 13.2.6.3.2 Deals
- 13.2.7 QIAGEN
- 13.2.7.1 Business overview
- 13.2.7.2 Products offered
- 13.2.7.3 Recent developments
- 13.2.8 ILLUMINA, INC.
- 13.2.8.1 Business overview
- 13.2.8.2 Products offered
- 13.2.8.3 Recent developments
- 13.2.8.3.1 Product launches & approvals
- 13.2.8.3.2 Deals
- 13.2.9 BIO-RAD LABORATORIES, INC.
- 13.2.9.1 Business overview
- 13.2.9.2 Products offered
- 13.2.9.3 Recent developments
- 13.2.9.3.1 Product launches & approvals
- 13.2.10 DIASORIN S.P.A.
- 13.2.10.1 Business overview
- 13.2.10.2 Products offered
- 13.2.10.3 Recent developments
- 13.2.11 STANDARD BIOTOOLS
- 13.2.11.1 Business overview
- 13.2.11.2 Product offered
- 13.2.11.3 Recent developments
- 13.2.11.3.1 Product launches & approvals
- 13.2.11.3.2 Deals
- 13.2.12 TECAN TRADING AG
- 13.2.12.1 Business overview
- 13.2.12.2 Products offered
- 13.2.13 SARTORIUS AG
- 13.2.13.1 Business overview
- 13.2.13.2 Products offered
- 13.2.13.3 Recent developments
- 13.2.14 CORNING INCORPORATED
- 13.2.14.1 Business overview
- 13.2.14.2 Products offered
- 13.2.15 CYTEK BIOSCIENCES
- 13.2.15.1 Business overview
- 13.2.15.2 Products offered
- 13.2.15.3 Recent developments
- 13.2.16 TAKARA BIO INC.
- 13.2.16.1 Business overview
- 13.2.16.2 Products offered
- 13.2.17 BIOMERIEUX
- 13.2.17.1 Business overview
- 13.2.17.2 Products offered
- 13.2.17.3 Recent developments
- 13.2.18 REVVITY
- 13.2.18.1 Business overview
- 13.2.18.2 Products offered
- 13.2.18.3 Recent developments
- 13.2.19 BIO-TECHNE
- 13.2.19.1 Business overview
- 13.2.19.2 Products offered
- 13.2.19.3 Recent developments
- 13.2.20 PACBIO
- 13.2.20.1 Business overview
- 13.2.20.2 Products offered
- 13.2.20.3 Recent developments
- 13.2.20.3.1 Product launches & approvals
- 13.2.21 BRUKER
- 13.2.21.1 Business overview
- 13.2.21.2 Products offered
- 13.2.21.3 Recent developments
- 13.2.21.3.1 Product launches & approvals
- 13.2.22 PROMEGA CORPORATION
- 13.2.22.1 Business overview
- 13.2.22.2 Products offered
- 13.2.23 OXFORD NANOPORE TECHNOLOGIES PLC
- 13.2.23.1 Business overview
- 13.2.23.2 Products offered
- 13.3 OTHER PLAYERS
- 13.3.1 SINGLERON BIOTECHNOLOGIES
- 13.3.2 CELL MICROSYSTEMS
- 13.3.3 NANOCELLECT BIOMEDICAL
- 13.3.4 RARECYTE, INC.
- 13.3.5 BICO
- 13.3.6 MENARINI GROUP
14 DISCUSSION GUIDE
- 14.1 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 14.2 CUSTOMIZATION OPTIONS
- 14.3 RELATED REPORTS
- 14.4 AUTHOR DETAILS